The AUA Expert Exchange Podcast: Discussions About Managing GU Cancer (2019)
To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Based on the documented need for additional education in prostate cancer, bladder cancer, and renal cell carcinoma, the AUA will identify expert faculty to engage in a series of 12 interactive interview-style episodes. The AUA Expert Exchange Podcast: Discussions About Managing GU Cancer is designed to address very specific learning opportunities and reach the urologist in an easy, flexible way with smaller, targeted updates.
The 12 topic-specific podcasts will focus on the follow:
1. Genetic Testing in Prostate Cancer
2. Comorbidities in Advanced Prostate Cancer
3. Treatment for Metastatic Hormone Sensitive Prostate Cancer (M-HSPC)
4. Sequencing of Agents and Combination Therapy in Prostate Cancer
5. The Role of Immune Checkpoint Inhibitors in Bladder Cancer
6. Sequencing of Agents and Combination of Treatment Options for Bladder Cancer
7. Chemo-ablation of Upper-Tract Urothelial Carcinoma
8. Clinical Investigations in the Treatment of Bladder Cancer
Renal Cell Carcinoma:
9. Adjuvant Therapy in RCC
10. Targeted Therapies in RCC
11. Immune Checkpoint Inhibitors in RCC
12. Sequencing of Agents and Combination of Treatment Options for RCC
This educational series is supported by independent educational grants from:
At the conclusion of these activities, participants will be able to:
Genetic Testing in Prostate Cancer
- State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
- Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.
- Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.
Comorbidities in Prostate Cancer
- Recognize cardiovascular comorbidities and describe their management in the context of prostate cancer treatment.
- Differentiate the roles of the urologist, other specialists and primary care providers in the care of patients with prostate cancer.
Treatment for Metastatic Hormone Sensitive Prostate Cancer (M-HSPC)
- Identify the active agents and their mechanism of action in the management of metastatic HSPC.
- Describe the risks and benefits of treatment for metastatic HSPC.
Sequencing of Agents and Combination Therapy in Castrate Resistant Prostate Cancer
- Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their administration.
- Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy.
- Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.
The Role of Immune Checkpoint Inhibitors in Bladder Cancer
- Recognize both historic and newer immunotherapy options in the treatment of bladder cancer.
- Describe the mechanism of action of immunotherapy regimens.
- Identify and manage the adverse events related to these agents.
Sequencing of Agents and Combination of Treatment Options for Bladder Cancer
- Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.
- Facilitate discussions with patients and caregivers regarding of bladder cancer treatment options.
Chemo-ablation of Upper-Tract Urothelial Carcinoma
- Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment.
- Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.
Clinical Investigations in the Treatment of Urothelial Carcinoma
- Explain the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and describe current clinical trial designs.
- List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.
Adjuvant Therapy in RCC
- Discuss the evolving landscape of adjuvant therapy for the treatment of RCC.
- Identify best practices for risk assessment and patient selection for adjuvant RCC therapy.
- Differentiate the roles of urologist and medical oncologist in the care of patients with RCC.
Targeted Therapies in RCC
- Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC.
- Facilitate discussions with patients and caregivers regarding RCC treatment options.
Immune Checkpoint Inhibitors in RCC
- Discuss the current immunotherapy options available for the treatment of RCC.
- Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.
- Identify and manage the adverse events related to these agents.
Sequencing of Agents and Combination of Treatment Options for RCC
- Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.
- Explain best practices in RCC patient selection for various treatment options
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 6.00 hours
Release Date: September, 2019
Expiration Date: December, 2020
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.